PETCMCaspase-3 activator CAS# 10129-56-3 |
- PD 123319 ditrifluoroacetate
Catalog No.:BCC1841
CAS No.:136676-91-0
- Irbesartan
Catalog No.:BCC2560
CAS No.:138402-11-6
- Olmesartan
Catalog No.:BCC1819
CAS No.:144689-24-7
- Tranilast
Catalog No.:BCC2514
CAS No.:53902-12-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 10129-56-3 | SDF | Download SDF |
PubChem ID | 224859 | Appearance | Powder |
Formula | C8H8Cl3NO | M.Wt | 240.52 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 50 mM in 1eq. HCl | ||
Chemical Name | 1,1,1-trichloro-3-pyridin-4-ylpropan-2-ol | ||
SMILES | C1=CN=CC=C1CC(C(Cl)(Cl)Cl)O | ||
Standard InChIKey | NGTDJJKTGRNNAU-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C8H8Cl3NO/c9-8(10,11)7(13)5-6-1-3-12-4-2-6/h1-4,7,13H,5H2 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Caspase-3 activator. Acts via inhibition of the oncoprotein ProT, therefore stimulates apoptosome formation and subsequent caspase-3 activation in a cytochrome c-dependent manner. |
PETCM Dilution Calculator
PETCM Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 4.1577 mL | 20.7883 mL | 41.5766 mL | 83.1532 mL | 103.9415 mL |
5 mM | 0.8315 mL | 4.1577 mL | 8.3153 mL | 16.6306 mL | 20.7883 mL |
10 mM | 0.4158 mL | 2.0788 mL | 4.1577 mL | 8.3153 mL | 10.3941 mL |
50 mM | 0.0832 mL | 0.4158 mL | 0.8315 mL | 1.6631 mL | 2.0788 mL |
100 mM | 0.0416 mL | 0.2079 mL | 0.4158 mL | 0.8315 mL | 1.0394 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
PETCM is an activator of caspase-3 [1].
Caspase-3 is a member of the cysteine-aspartic acid protease family and interacts with caspase-8 and caspase-9. Sequential activation of caspases plays an important role in cell apoptosis.
In HeLa S-100 cell cytosol, PETCM activated caspase-3 in a dose-dependent way and induced apoptosome formation. PETCM (0.2 mM) caused Apaf-1 shifted to a size of ~1 million daltons, which indicating apoptosome formation. Also, PETCM function required dATP. The activation effect of PETCM on caspase-3 was independent of PHAP proteins. When inhibited the activation activity of the PHAP proteins, PETCM reversed the suppression. When added to Q30 (Apaf-1/procaspase-9) plus cytochrome c and 10 μM dATP, recombinant PHAPI activated caspase-3. The activity was inhibited by recombinant ProT. While, PETCM reversed the inhibitory effect of ProT. PHAPI didn’t affect apoptosome formation and activated caspase-9 and Apaf-1, which were associated with apoptosome. ProT efficiently blocked formation of apoptosome and PETCM relieved this effect [1].
Reference:
[1]. Jiang X, Kim HE, Shu H, et al. Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science, 2003, 299(5604): 223-226.
- 11-Chloro-2,3-dihydro-2-methyl-1H- dibenz[2,3:6,7]oxepino[4,5-c]pyrrol-1-one
Catalog No.:BCC8431
CAS No.:1012884-46-6
- Phenserine
Catalog No.:BCC7529
CAS No.:101246-66-6
- Kushenol M
Catalog No.:BCN3310
CAS No.:101236-51-5
- Kushenol L
Catalog No.:BCN3309
CAS No.:101236-50-4
- Kushenol K
Catalog No.:BCN3448
CAS No.:101236-49-1
- IRAK inhibitor 3
Catalog No.:BCC1656
CAS No.:1012343-93-9
- Picrasidine Q
Catalog No.:BCN3182
CAS No.:101219-61-8
- IRAK inhibitor 4
Catalog No.:BCC1657
CAS No.:1012104-68-5
- CUDC-101
Catalog No.:BCC2149
CAS No.:1012054-59-9
- Longipedlactone J
Catalog No.:BCN6644
CAS No.:1011762-93-8
- Momordicoside P
Catalog No.:BCN3275
CAS No.:1011726-62-7
- Tenovin-6
Catalog No.:BCC3667
CAS No.:1011557-82-6
- Noreugenin
Catalog No.:BCN5827
CAS No.:1013-69-0
- Zacopride hydrochloride
Catalog No.:BCC7178
CAS No.:101303-98-4
- PF-04691502
Catalog No.:BCC3837
CAS No.:1013101-36-4
- Formosanol
Catalog No.:BCN5826
CAS No.:101312-79-2
- Gadolinium chloride
Catalog No.:BCC7971
CAS No.:10138-52-0
- CP 376395 hydrochloride
Catalog No.:BCC7604
CAS No.:1013933-37-3
- VTP-27999 2,2,2-trifluoroacetate
Catalog No.:BCC2049
CAS No.:1013937-63-7
- GSK 0660
Catalog No.:BCC7688
CAS No.:1014691-61-2
- 5''-O-Syringoylkelampayoside A
Catalog No.:BCN4798
CAS No.:1014974-98-1
- Methyl salvionolate A
Catalog No.:BCN3475
CAS No.:1015171-69-3
- Latifolin
Catalog No.:BCN7778
CAS No.:10154-42-4
- Fmoc-D-Pro-OH
Catalog No.:BCC3540
CAS No.:101555-62-8
Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway.[Pubmed:12522243]
Science. 2003 Jan 10;299(5604):223-6.
A small molecule, alpha-(trichloromethyl)-4-pyridineethanol (PETCM), was identified by high-throughput screening as an activator of caspase-3 in extracts of a panel of cancer cells. PETCM was used in combination with biochemical fractionation to identify a pathway that regulates mitochondria-initiated caspase activation. This pathway consists of tumor suppressor putative HLA-DR-associated proteins (PHAP) and oncoprotein prothymosin-alpha (ProT). PHAP proteins promoted caspase-9 activation after apoptosome formation, whereas ProT negatively regulated caspase-9 activation by inhibiting apoptosome formation. PETCM relieved ProT inhibition and allowed apoptosome formation at a physiological concentration of deoxyadenosine triphosphate. Elimination of ProT expression by RNA interference sensitized cells to ultraviolet irradiation-induced apoptosis and negated the requirement of PETCM for caspase activation. Thus, this chemical-biological combinatory approach has revealed the regulatory roles of oncoprotein ProT and tumor suppressor PHAP in apoptosis.
Direct activation of the apoptosis machinery as a mechanism to target cancer cells.[Pubmed:12808146]
Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7533-8.
Apoptosis plays a pivotal role in the cytotoxic activity of most chemotherapeutic drugs, and defects in this pathway provide a basis for drug resistance in many cancers. Thus the ability to restore apoptosis by using small molecules could have important therapeutic implications. Using a cell-free assay to simultaneously target multiple components of the apoptosis pathway, we identified a class of compounds that activate caspases in a cytochrome c-dependent manner and induce apoptosis in whole cells. By reconstituting the apoptosis pathway with purified proteins, we determined that these compounds promote the protein-protein association of Apaf-1 into the functional apoptosome. These compounds exert cytostatic and cytotoxic effects on a variety of cancer cell lines while having little or no activity against the normal cell lines tested. These findings suggest that direct activation of the basic apoptosis machinery may be a viable mechanism to selectively target cancer.